This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D81.6 (MHC class I deficiency) | OMIM: 604571 (TAP1 deficiency), 604572 (TAP2 deficiency), 610654 (Tapasin deficiency) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | MHC class I deficiency, Bare lymphocyte syndrome type I (BLS I), TAP deficiency, Tapasin deficiency, HLA class I deficiency |
| C. Adult onset | Likelihood of first onset in adulthood present (moderate) — MHC class I deficiency has a milder clinical phenotype than MHC class II deficiency or other SCIDs, and cases have been reported that were asymptomatic in childhood and first diagnosed in adulthood with recurrent respiratory infections or bronchiectasis. Adult-onset cases exist, particularly in TAP deficiency. |
| 1. History | 1985, first description of bare lymphocyte syndrome (BLS) → 1989, classification into MHC class I and class II → 1990s, TAP1, TAP2, and Tapasin deficiencies identified as the molecular causes of BLS I → classified as ICD-10 D81.6. |
| 2. Causes | Variants in the TAP1 (6p21.32), TAP2 (6p21.32), or Tapasin (TAPBP, 6p21.32) gene → impaired antigen presentation pathway → loss of MHC I molecule expression on the cell surface → reduced CD8+ T-cell and NK cell function. |
| 3. Genetics | Autosomal recessive (AR). TAP1, TAP2, and TAPBP are all located at 6p21.32 (within the MHC complex). Numerous missense, nonsense, and splicing variants reported. Specific founder variants identified in people of North African descent. |
| 4. General epidemiology | About 50–80 cases reported worldwide. Concentrated in North Africa (Morocco, Algeria, etc.). Equal in males and females. Very few cases in Korea. |
| 5. Pathophysiology | TAP deficiency → failure of transport of endogenous antigen peptides into the ER → unstable MHC I molecules → reduced cell surface expression → impaired positive selection of CD8+ T cells and NK cell activation. |
| 6. Symptoms | Recurrent respiratory infections (bacterial pneumonia, sinusitis), bronchiectasis, granulomatous skin lesions, vasculitis. Relatively mild clinical course compared with MHC class II deficiency. |
| 7. Signs | Marked reduction of CD8+ T cells, reduced NK cells, normal CD4+ T cells, normal immunoglobulins, loss of MHC I expression on flow cytometry, absent HLA-A/B/C expression. |
| 8. Screening | TREC screening (total T-cell count may be normal), HLA I expression on flow cytometry, early genetic testing based on family history. |
| 9. Diagnosis | Flow cytometry (CD8↓, loss of HLA I expression), T-cell function tests, molecular genetic testing (TAP1/TAP2/TAPBP), histopathology (with skin granulomas). |
| 10. Treatment | HSCT (some patients), prophylactic antibiotics, IVIG, management of bronchiectasis. Topical treatment of skin granulomas. Gene therapy under study. |
| 11. Prognosis | Better survival than MHC class II deficiency. Some survive into adulthood. Bronchiectasis and declining lung function are the main sources of morbidity. Granulomatous lesions may persist. |
| 12. Prevention | Genetic counseling, PGT/prenatal diagnosis, prevention of recurrent infections, strategies to protect lung function, live vaccines contraindicated. |
| 13. References | De la Salle H et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency … and 9 other papers |
The history of major histocompatibility complex (MHC) class I deficiency, that is, Bare lymphocyte syndrome type I (BLS type I), arose as the functions of MHC molecules were gradually elucidated alongside advances in immunology. In the early 1980s, immunologists began observing unusual patients lacking MHC molecules on the lymphocyte surface. The name "Bare lymphocyte syndrome" itself describes lymphocytes that are literally 'bare' because they lack HLA (human leukocyte antigen) molecules on the cell surface.
In 1985, a French research team including Griscelli, Lisowska-Grospierre, and Durandy systematically described cases of children with immunodeficiency lacking MHC II molecule expression. Separately, it was also confirmed that some patients had a type specifically lacking MHC I molecule expression. From 1989 on, these two types were classified according to their clinical and genetic features as Bare lymphocyte syndrome type I (BLS I, MHC I deficiency) and type II (BLS II, MHC II deficiency), respectively. It became clear that the clinical phenotypes differ: in BLS I, reduced CD8+ T cells and NK cell abnormalities are prominent, whereas in BLS II, impaired CD4+ T-cell function and failure of antibody responses are the main findings.
In the early 1990s, the function of the TAP (Transporter associated with Antigen Processing) protein complex, which plays a key role in antigen presentation by MHC I molecules, was elucidated. The TAP protein transports peptide fragments generated by the proteasome in the cytoplasm into the lumen of the endoplasmic reticulum (ER), where they bind MHC I molecules. In 1994, De la Salle and colleagues first identified a homozygous mutation of the TAP1 gene in a BLS I patient, and TAP2 gene variants were subsequently confirmed as a cause of BLS I. BLS I thus came to be understood not as a simple abnormality of MHC I expression but as a disorder of the antigen processing and presentation pathway caused by variants in TAP1, TAP2, or the Tapasin (tapA/TAPBP) gene that regulates them.
From the late 1990s through the 2000s, Tapasin (TAPBP, tapasin) deficiency was identified as the third causative gene. Tapasin is a molecular chaperone that links the TAP complex with the MHC I-β2-microglobulin dimer and is essential for optimizing MHC I binding to high-affinity peptides. In Tapasin deficiency, the stability of the MHC I-peptide complex is reduced and cell surface expression decreases. Through these molecular findings, MHC I deficiency became established as an immunodeficiency caused by deficiency of components of the antigen presentation machinery (APM). Since the 2000s, case reports have accumulated worldwide, and TAP2 deficiency due to a founder mutation has been reported in concentration particularly in patient groups from North Africa (Morocco, Algeria, Tunisia). It is classified as D81.6 in ICD-10 and managed in Orphanet under subtype-specific codes such as ORPHA:34/ORPHA:572/ORPHA:94.
In Korea, case reports of MHC class I deficiency are extremely rare, and diagnosis rates are expected to rise with expansion of diagnostic infrastructure and dissemination of molecular diagnostic techniques. Because this disease has a milder clinical course than other SCID types and some patients survive into adulthood, it should be included in the differential diagnosis even for patients who visit adult pulmonology or immunology clinics with recurrent respiratory infections or bronchiectasis.
The cause of MHC class I deficiency (BLS I) is pathogenic variants in genes encoding key proteins involved in the endogenous antigen presentation pathway. Three causative genes have been identified to date.
First, variants in the TAP1 (Transporter 1, ATP Binding Cassette Subfamily B Member) gene (ABCB9 or TAP1, Gene ID: 6890, 6p21.32). The TAP1 protein forms a dimer with the TAP2 protein and functions as an ATP-dependent ABC transporter (ATP-binding cassette transporter). This transporter actively transports peptide fragments derived from endogenous proteins degraded by the proteasome in the cytoplasm (mainly 8–10 amino acids long) into the ER lumen.
Second, variants in the TAP2 (Transporter 2, ATP Binding Cassette Subfamily B Member) gene (ABCB3 or TAP2, Gene ID: 6891, 6p21.32). TAP2 pairs with TAP1 to form the TAP dimer and mediates energy-dependent peptide transport through its ATP-binding domain. TAP2 deficiency causes a phenotype similar to TAP1 deficiency, and a founder variant (c.1879G>A, p.Ala627Thr) is reported relatively frequently in patients of North African descent.
Third, variants in the Tapasin (TAPBP) gene (TAPBP, Gene ID: 6892, 6p21.32). Tapasin is a molecular chaperone that links the TAP1/TAP2 dimer, the MHC I-β2-microglobulin dimer, ERp57 (a PDI-family oxidoreductase), and calreticulin, and is a key component of the PLC (peptide-loading complex). When Tapasin is deficient, MHC I molecules remain in an unstable empty form (empty MHC I-β2m heterodimer) or are degraded in the ER while incompletely folded, so expression on the cell surface is markedly reduced.
A notable feature is that all three of these genes are clustered at 6p21.32 within the MHC gene complex. When a homozygous or compound heterozygous pathogenic variant occurs in a causative gene, TAP1/TAP2/Tapasin function is lost, making ER transport of endogenous peptides and formation of MHC I-peptide complexes impossible. As a result, MHC I molecules are not expressed or are markedly reduced on the cell surface. Without MHC I molecules, CD8+ T cells (cytotoxic T lymphocytes, CTL) cannot recognize the cells, so immune surveillance against intracellular viral infection or tumor cells becomes impossible. In addition, NK cells normally recognize MHC I-expressing cells as 'self' and suppress attack, but for cells lacking MHC I this inhibitory signal is lost and NK cells are activated. Paradoxically, however, some NK cell attack directed at self cells in these patients is presumed to contribute to the development of inflammatory lesions such as skin granulomas.
MHC class I deficiency follows an autosomal recessive (AR) mode of inheritance. The causative genes TAP1, TAP2, and TAPBP (Tapasin) are all located on chromosome 6p21.32, within the MHC complex where the classical MHC genes (HLA-A, HLA-B, HLA-C, etc.) are clustered. Because all three genes lie within a relatively narrow region, linkage disequilibrium within the same haplotype contributes to the concentrated occurrence of specific founder variants.
The TAP1 gene (about 11 kb, 11 exons) and the TAP2 gene (about 10 kb, 11 exons) are transcribed in opposite directions and encode proteins of about 81 kDa (TAP1) and 75 kDa (TAP2), respectively. Both proteins have a structure with N-terminal multiple transmembrane domains and a C-terminal ATP-binding cassette (NBD, nucleotide binding domain), and function after dimerizing and inserting into the ER membrane. The TAPBP gene is about 20 kb with 9 exons, and the protein has a molecular weight of about 48 kDa.
Reported types of pathogenic variants include missense variants, nonsense variants, splice site variants, and small insertions/deletions, all of which cause loss or marked reduction of protein function. In TAP2 deficiency, the c.1879G>A (p.Ala627Thr) variant has been reported as a founder variant among patients of North African descent; this variant lies in the ATP-binding domain and inhibits ATPase activity. In TAP1 deficiency, variants such as c.584A>G (p.Tyr195Cys) have also been reported. Relatively few cases of Tapasin deficiency have been reported, but nonsense and splicing variants, among others, have been described in the literature.
Regarding genotype-phenotype correlation, TAP1 and TAP2 deficiencies often lead to complete loss of MHC I expression and show clinically similar phenotypes. In Tapasin deficiency, MHC I expression is sometimes not completely lost but partly retained, and clinical symptoms tend to be relatively mild. Carrier parents have TAP expression reduced to about 50% but are clinically asymptomatic with normal MHC I expression. For molecular genetic diagnosis, NGS of a primary immunodeficiency panel including the TAP1, TAP2, and TAPBP genes, or WES, is applied. After the variant in the family is identified, carrier testing, genetic counseling, and prenatal/preimplantation diagnosis options are offered.
MHC class I deficiency (BLS I) is a very rare disease worldwide. Since the first molecular confirmation in 1994, an estimated 50–80 cases had been reported in the literature worldwide by the early 2020s. No official incidence figure has been established, but it is understood to account for a tiny fraction of all primary immunodeficiencies (about 1/10,000 births).
Geographically, the most notable feature is that it is reported at a disproportionately high frequency in patients from North Africa, especially Morocco, Algeria, and Tunisia. This is because a founder variant causing TAP2 deficiency exists in specific populations of this region, and the cultural practice of consanguinity increases the frequency of autosomal recessive diseases. In France, patients from North African immigrant families have been reported in concentration, and major clinical research on BLS I has been conducted mainly at Necker Children's Hospital in Paris.
In keeping with autosomal recessive inheritance, males and females can be equally affected. Because BLS I has a milder clinical phenotype than BLS II (MHC class II deficiency, D81.7), diagnosis may be delayed or missed in childhood in some patients, and cases first diagnosed in adulthood have also been reported. This suggests that the actual number of affected patients may be greater than the reported cases.
In Korea, confirmed cases of BLS I are very rare and no public statistics are available. Only a small number of registrations are expected in Korean primary immunodeficiency registration data (Health Insurance Review & Assessment Service (HIRA) code D81.6) as well. Information on the causative gene variants occurring mainly in Korean patients has not yet been sufficiently accumulated.
Orphanet manages TAP1 deficiency (ORPHA:572), TAP2 deficiency (ORPHA:573), and Tapasin deficiency (ORPHA:94) as separate entries. MHC class I deficiency as a whole is covered by ICD-10 D81.6, and OMIM registers TAP1 deficiency as OMIM 604571, TAP2 deficiency as OMIM 604572, and Tapasin deficiency as OMIM 610654.
The core pathogenesis of MHC class I deficiency is understood as a defect in the endogenous antigen presentation pathway (MHC I-restricted antigen presentation pathway), a sequence of events running from loss of TAP or Tapasin protein function → inability to form MHC I-peptide complexes in the ER → loss of cell surface MHC I expression → CD8+ T-cell and NK cell dysfunction.
In normal cells, endogenous proteins (self proteins or intracellular viral proteins) are degraded by the cytoplasmic ubiquitin-proteasome system (UPS) into peptide fragments 8–10 amino acids long. These peptides are actively transported into the endoplasmic reticulum (ER) lumen by the TAP1/TAP2 dimer in an ATP-dependent manner. In the ER lumen, peptides are loaded onto MHC I molecules in the peptide loading complex (PLC), composed of TAP, Tapasin, the MHC I heavy chain, β2-microglobulin (β2m), ERp57, and calreticulin. The MHC I-β2m-peptide trimer bound to a peptide of appropriate affinity is structurally stabilized, transported to the cell surface via the Golgi apparatus, and recognized by CD8+ T cells, enabling immune surveillance.
In TAP1 or TAP2 deficiency, cytoplasm-derived peptides cannot be transported to the ER. Without peptides, the MHC I heavy chain and β2m form a transient dimer, but these empty MHC I molecules are unstable and are degraded in the ER or, even if they move to the cell surface, soon dissociate. As a result, MHC I expression on the cell surface is markedly reduced. In Tapasin deficiency, TAP function itself is preserved, but the MHC I-β2m dimer cannot be efficiently linked to TAP and high-affinity peptide loading does not occur, so formation of stable MHC I trimers is reduced.
In the thymus, CD8+ T cells must receive a survival signal during positive selection, based on weak affinity for MHC I-peptide complexes on the surface of cortical thymic epithelial cells (cortical TEC), in order to mature. When MHC I expression is reduced, this positive selection signal is insufficient, resulting in reduced intrathymic maturation of CD8+ T cells and reduced peripheral numbers. In contrast, because CD4+ T cells are positively selected by MHC II molecules, CD4+ T-cell numbers remain normal in MHC I deficiency. NK cells normally suppress attack on self cells through inhibitory receptors (KIR, NKG2A/CD94) for MHC I-expressing cells, but in patients with MHC I deficiency, self cells do not express MHC I, so the NK cell inhibitory signal is lost. As a result, NK cells attack self cells, and this has been proposed as the mechanism of unusual skin lesions such as cutaneous necrotizing granulomas. In addition, NK cell surveillance of virus-infected cells or tumor cells may not function normally, increasing susceptibility to certain viruses and tumors.
The clinical symptoms of MHC class I deficiency (BLS I) are generally milder than those of MHC class II deficiency (BLS II) or other SCID types and are characterized mainly by susceptibility to viral infections and chronic lung disease due to impaired CD8+ T-cell and NK cell function, together with distinctive skin lesions.
The most common and clinically important group of symptoms is recurrent respiratory infection. Recurrent bacterial pneumonia and recurrent purulent sinusitis due to pneumococcus, Haemophilus influenzae, Staphylococcus aureus, and others occur. As a result of recurrent lung infections, bronchiectasis develops, and this is the main mechanism of long-term decline in lung function in BLS I patients. As bronchiectasis progresses, chronic cough, copious purulent sputum, dyspnea, and an obstructive ventilatory pattern on pulmonary function tests appear. Mycobacterial (Mycobacterium) infections, especially non-tuberculous mycobacteria (NTM) infections, have been reported in patients with MHC I deficiency, so active investigation for these is needed in patients with recurrent lung infections. Susceptibility to viral infections such as CMV, EBV, and HSV is also increased, but life-threatening opportunistic infections are less frequent than in other SCIDs.
One of the characteristic findings of BLS I is necrotizing granulomatous skin lesions. These skin lesions, which occur on the face, nose, limbs, and elsewhere, show granulomatous inflammation on skin biopsy, with characteristic perivascular and intravascular inflammatory cell infiltration. These skin lesions are understood not as a direct result of bacterial or viral infection but as an autoinflammatory reaction due to NK cell activation and immune dysregulation. In some patients the skin lesions recur repeatedly and respond poorly to treatment, and in severe cases they progress to necrosis and ulceration. A cutaneous vasculitis pattern has also been reported.
Autoimmune phenomena may accompany the disease in some patients, and inflammatory bowel disease-like enteritis has also been reported. In general, severe opportunistic infections (PJP, disseminated candidiasis, etc.) are infrequent in BLS I, and because B-cell function is relatively preserved and antibody production is possible, humoral immunity-based defense is maintained to a certain level. However, because of CD8+ T-cell deficiency, the ability to control intracellular viral infections (especially EBV, CMV, and human papillomavirus HPV) is reduced.
The laboratory and physical signs of MHC class I deficiency are characterized as follows.
General condition is often relatively good compared with MHC class II deficiency or other SCIDs. As a result of recurrent lung infections, crackles due to bronchiectasis may be heard on auscultation, and bronchial wall thickening and bronchiectasis are observed on chest X-ray or CT. Granulomatous skin lesions may be seen on the face (nasal area) or limbs, sometimes with reddish-brown discoloration or ulceration of the skin. Reactive lymph node enlargement may be relatively mild or absent.
On peripheral blood flow cytometry, the most characteristic finding of BLS I is a marked reduction of CD8+ T cells (cytotoxic T lymphocytes). CD8+ T-cell counts are often reduced to 10–20% of normal or less, and in severe cases CD8+ T cells are barely detectable. In contrast, CD4+ T cells are within the normal range, and the total lymphocyte count is often near normal. This is one reason BLS I may not be detected by TREC-based newborn screening (because TREC reflects the total T-cell count, the TREC reduction may not be clear if CD4+ T cells are normal). NK cells (CD16+CD56+) also tend to be reduced. Serum immunoglobulins (IgG, IgA, IgM) are within the normal range, and antibody responses to T cell-dependent antigens are relatively preserved. This is because CD4+ T cells are preserved and their helper function for B cells is maintained.
HLA class I expression analysis is the key to diagnosis. When HLA-A, HLA-B, and HLA-C expression on the surface of peripheral blood monocytes and lymphocytes is measured by flow cytometry, marked reduction or loss (negative) is confirmed in BLS I. In contrast, HLA class II (HLA-DR, DP, DQ) expression is normal. Loss of HLA expression confirmed on flow cytometry is strong diagnostic evidence for BLS I. Functional tests such as confirmation of TAP protein expression (immunoblot or flow cytometry) and measurement of TAP function in the ER (radioisotope peptide transport assay) are also used.
Newborn screening for MHC class I deficiency is more challenging than for other SCID types, because CD4+ T cells are relatively normal and the disease may therefore not be detected by TREC-based screening.
The TREC test mainly reflects new production of total T cells (thymopoiesis), measuring CD4+ and CD8+ T-cell production together. In MHC class I deficiency, CD8+ T cells are reduced but CD4+ T cells are normal, so the total TREC amount may appear normal or borderline, and the disease may be missed by TREC-based screening. Therefore, newborn TREC screening alone may not allow early detection of BLS I patients, and family history-based screening is more important.
When there is an affected family member or carrier parents have been identified, flow cytometry (HLA class I expression, T-cell subset analysis) and molecular genetic testing (TAP1/TAP2/TAPBP variant analysis) are performed from immediately after birth. This allows the diagnosis to be confirmed in the neonatal period and an early treatment plan to be established.
In children or adults with recurrent respiratory infections or unexplained chronic lung disease, basic immune tests (serum immunoglobulins, lymphocyte typing) are performed, and checking the CD8+ T-cell count in particular is an important clue to detecting BLS I. When a pattern of markedly reduced CD8+ T cells with normal immunoglobulins and preserved CD4+ T cells is observed, testing to confirm HLA class I expression follows.
In patients from North Africa (Morocco, Algeria, etc.) or of North African descent, when recurrent lung infections, reduced CD8+ T cells, and loss of HLA I expression are confirmed, targeted analysis for the TAP2 founder variant (c.1879G>A) can be performed first, improving diagnostic efficiency.
MHC class I deficiency is confirmed through immunophenotyping, HLA expression testing, and molecular genetic testing.
Peripheral blood flow cytometry measures the counts and proportions of T-cell subsets (CD3+, CD4+, CD8+), B cells (CD19+), and NK cells (CD16+CD56+). The typical pattern of BLS I is a marked reduction of CD8+ T cells (often < 50/μL or 5–20% of normal), normal CD4+ T cells, and reduced or normal NK cells.
HLA-A/B/C expression on the surface of peripheral blood lymphocytes and monocytes is quantified by flow cytometry using a pan-HLA class I antibody (e.g., the W6/32 monoclonal antibody). In BLS I, HLA class I expression is markedly reduced or negative (<5% or less than 10% of normal). HLA class II (HLA-DR) expression must be normal to presume BLS I (in BLS II, conversely, HLA II expression is lost).
T-cell proliferative responses to mitogen (PHA) stimulation are often relatively preserved or mildly reduced in BLS I. Serum IgG, IgA, and IgM are confirmed to be within the normal range. This helps differentiate it from BLS II and other SCIDs.
The causative variant is confirmed by sequencing of the TAP1, TAP2, and TAPBP genes (primary immunodeficiency panel NGS or targeted Sanger sequencing). In patients of North African descent, the TAP2 founder variant is targeted first, followed by confirmation with full gene analysis.
Bronchiectasis and structural lung changes are evaluated by high-resolution lung CT (HRCT). When granulomatous skin lesions are present, skin biopsy is performed to confirm the histopathology (perivascular and intravascular granulomatous inflammation, necrosis). Sputum culture and bronchoalveolar lavage (BAL) testing are considered to check for mycobacterial (including NTM) infection.
Differentiation is needed from BLS II (MHC class II deficiency, D81.7: reduced CD4+ T cells, loss of HLA II expression), other SCID types, DiGeorge syndrome (thymic hypoplasia, reduction of both CD4+ and CD8+, 22q11.2 deletion), and secondary CD8+ T-cell reduction due to chronic viral infection (excluding HIV infection).
Treatment of MHC class I deficiency should be individualized according to disease severity and clinical presentation. Because BLS I has a milder clinical course than other SCID types, hematopoietic stem cell transplantation (HSCT) is not uniformly recommended for all patients and is decided on the basis of a risk-benefit analysis.
HSCT can provide curative treatment in some BLS I patients. When immune cells with normal TAP function are reconstituted after transplantation of hematopoietic stem cells from a normal donor, HLA I expression and CD8+ T-cell function can recover. However, no consensus guidelines have been established on the indications and timing of HSCT in BLS I, and progression of bronchiectasis due to recurrent lung infections, severe inflammation and ulceration of skin granulomas, or severe viral infections are applied as criteria for deciding on HSCT. Large cohort data on post-transplant outcomes are lacking, but prevention of further progression of bronchiectasis and improvement of skin lesions have been reported in successfully transplanted cases.
Prophylactic antibiotics are considered to prevent recurrent bacterial lung infections. Pneumococcal protein conjugate vaccine (PCV; can be given because it is inactivated) and inactivated influenza vaccine are recommended. When mycobacterial infection is confirmed, long-term antimycobacterial therapy is given. IVIG may be considered in some patients to prevent recurrent infections even if serum immunoglobulins are normal. Live vaccines (BCG, MMR, varicella, etc.) are contraindicated.
For bronchiectasis that has already developed, management includes regular pulmonary function evaluation, airway clearance therapy, regular antibiotics for chronic bacterial colonization (e.g., inhaled antibiotics), and pulmonary rehabilitation.
For granulomatous skin lesions, topical immunomodulatory treatments such as topical steroids and tacrolimus ointment are tried. For severe skin lesions, systemic steroids or other immunosuppressants may be considered, but caution is needed because they can worsen the immunodeficient state.
Gene therapy that introduces the TAP1 or TAP2 gene into autologous hematopoietic stem cells via a lentiviral vector is being examined at the preclinical research stage. Autologous gene correction has the theoretical advantage of restoring MHC I expression without GVHD risk, but sufficient data for clinical application have not yet accumulated.
The prognosis of MHC class I deficiency (BLS I) is generally better than that of severe T-cell deficiencies such as MHC class II deficiency or ADA/PNP deficiency. Some patients survive into adulthood, and some go undiagnosed until adulthood. However, progression of bronchiectasis is the main cause of long-term morbidity and mortality.
Respiratory prognosis: recurrent lung infections and progression of bronchiectasis are the key determinants of long-term prognosis. As bronchiectasis progresses, lung function declines gradually and may lead to chronic respiratory failure. There are reports that lung function is relatively well maintained in patients diagnosed early who receive active bronchiectasis management (physiotherapy, regular antibiotics, pulmonary rehabilitation) and prophylactic anti-infective treatment.
Prognosis of skin lesions: granulomatous skin lesions often follow a chronic relapsing course, and severe necrosis and scarring may occur. Cases of skin lesion improvement after successful HSCT have been reported, suggesting that immune reconstitution can suppress skin pathology related to NK cell activation.
Infection-related prognosis: CD8+ T-cell deficiency increases susceptibility to intracellular viral (CMV, EBV, HPV) infections, and there is also a risk of EBV-related lymphoproliferative disease. When mycobacterial infection is confirmed, long-term treatment is needed and the risk of recurrence is high.
Prognosis after HSCT: when HSCT is performed and CD8+ T-cell reconstitution and recovery of HLA I expression are achieved after successful transplantation, a reduction in recurrent infections, stabilization of bronchiectasis, and improvement of skin lesions are expected. However, because large-scale data on HSCT outcomes in BLS I are lacking, the accuracy of prognostic prediction is limited.
Overall, the long-term prognosis of BLS I varies greatly depending on early diagnosis, active management of lung infections, and whether HSCT is performed when needed. Active management to preserve lung function is important even in patients diagnosed in adulthood, and multidisciplinary management at a primary immunodeficiency center is recommended.
Prevention of MHC class I deficiency is organized into primary prevention, which prevents occurrence of the disease itself; secondary prevention, which minimizes infectious complications; and tertiary prevention, which prevents progression of complications that have already developed.
Because the parents of an affected child are carriers, there is a 25% risk of an affected child in the next pregnancy. With a genetic counseling specialist, options are discussed such as selection of unaffected embryos through preimplantation genetic testing (PGT) or prenatal genetic diagnosis using chorionic villus sampling/amniocentesis. This can be done rapidly and efficiently, particularly when a founder variant is known in families of North African descent.
In newborns with a family history, early immunophenotyping (HLA I expression, CD8+ T-cell proportion) is performed to bring diagnosis forward. After diagnosis, prophylactic antibiotics (to prevent recurrent lung infections), vaccination (only inactivated vaccines allowed; pneumococcal protein conjugate vaccine, inactivated influenza vaccine), early physiotherapy to prevent bronchiectasis, and absolute avoidance of live vaccines are implemented.
To prevent progression of bronchiectasis, regular pulmonary function tests (spirometry, chest HRCT), active airway clearance therapy, monitoring of bacterial colonization, and preemptive antibiotic treatment are carried out. Regular dermatologic follow-up and topical treatment of skin granulomas are maintained. Comprehensive support is provided, including psychological support for the family and information on patient organizations (Korean Primary Immunodeficiency Patients' Association, ESID, Jeffrey Modell Foundation).
De la Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science. 1994;265(5169):237–241. DOI: 10.1126/science.7517574. PMID: 7517574.
Furukawa H, Murata S, Yabe T, et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. Journal of Clinical Investigation. 1999;103(5):755–758. DOI: 10.1172/JCI5687. PMID: 10074493.
Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clinical and Experimental Immunology. 2000;121(2):173–178. DOI: 10.1046/j.1365-2249.2000.01264.x. PMID: 10931129.
Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354(9190):1598–1603. DOI: 10.1016/S0140-6736(99)04166-7. PMID: 10560672.
Zimmer J, Andres E, Donato L, Hanau D, Hentges F, de la Salle H. Clinical and immunological aspects of HLA class I deficiency. QJM: An International Journal of Medicine. 2005;98(10):719–727. DOI: 10.1093/qjmed/hci112. PMID: 16105870.
Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. Journal of Pediatrics. 1995;127(6):895–900. DOI: 10.1016/S0022-3476(95)70030-1. PMID: 7490527.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.
Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. Journal of Clinical Immunology. 2020;40(1):66–81. DOI: 10.1007/s10875-019-00722-4. PMID: 32048120.
de la Salle H, Zimmer J, Fricker D, et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. Journal of Clinical Investigation. 1999;103(5):R9–R13. DOI: 10.1172/JCI5687. PMID: 10074499.
Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annual Review of Genomics and Human Genetics. 2013;14:301–323. DOI: 10.1146/annurev-genom-091212-153455. PMID: 23875796.